Clinical bottom line
Pediatric autoimmune inner ear disease (AIED) is a rare but potentially reversible cause of progressive sensorineural hearing loss and vestibular symptoms in children. Recent advances in diagnostic criteria, immunologic testing, and imaging have improved early recognition. Prompt initiation of immunosuppressive therapy, primarily corticosteroids, can stabilize or improve hearing outcomes in many cases. However, diagnosis remains challenging due to nonspecific clinical features and lack of definitive biomarkers. Multidisciplinary management and close audiologic monitoring are essential to optimize outcomes.
What the evidence shows
AIED is characterized by an immune-mediated attack on inner ear structures, leading to fluctuating or progressive sensorineural hearing loss, often accompanied by vestibular dysfunction (Rauch et al., 2005). Although more commonly described in adults, pediatric cases are increasingly recognized, underscoring the need for heightened clinical suspicion (Semo et al., 2019).
Recent reviews highlight that diagnosis relies on a combination of clinical presentation, exclusion of other causes, and supportive laboratory and imaging findings (Liu et al., 2025). Autoantibody panels targeting inner ear antigens may aid diagnosis but lack sensitivity and specificity, limiting their standalone utility (Muhammad et al., 2026). Advanced MRI techniques can detect cochlear inflammation or endolymphatic hydrops, providing adjunctive diagnostic information (SpringerReference, 2024).
Therapeutically, corticosteroids remain the first-line treatment, with evidence showing that early initiation correlates with better hearing preservation or improvement (Semo et al., 2019; Rauch et al., 2005). For steroid-refractory cases, immunosuppressive agents such as methotrexate or biologics have been used with variable success, although pediatric data are limited (Muhammad et al., 2026). Long-term follow-up is critical due to the risk of relapse and progressive hearing loss.
Caveats and uncertainty
The rarity of pediatric AIED and the absence of standardized diagnostic criteria contribute to diagnostic delays and under-recognition (Liu et al., 2025). Autoantibody testing is not definitive, and false positives/negatives complicate interpretation (Muhammad et al., 2026). Imaging findings are supportive but not pathognomonic.
Therapeutic evidence is primarily derived from small case series and adult studies, limiting generalizability to children (Rauch et al., 2005). The optimal duration and dosing of immunosuppressive therapy remain unclear, and long-term safety data in pediatric populations are sparse (Semo et al., 2019). Additionally, distinguishing AIED from other causes of pediatric sensorineural hearing loss, such as genetic or infectious etiologies, requires careful evaluation.
How this may change practice
Clinicians should consider AIED in the differential diagnosis of unexplained progressive or fluctuating sensorineural hearing loss in children, especially when accompanied by vestibular symptoms or systemic autoimmune features. Early referral to otolaryngology and immunology specialists is advisable.
Incorporating comprehensive immunologic testing and advanced imaging may facilitate earlier diagnosis. Prompt initiation of corticosteroid therapy, tailored to pediatric dosing guidelines, may improve hearing outcomes. For refractory cases, multidisciplinary discussion regarding immunosuppressive options is warranted.
Regular audiologic monitoring and patient/family education about the chronic and relapsing nature of AIED are essential. Future research should focus on validating pediatric-specific diagnostic criteria and optimizing immunomodulatory treatment protocols.